Mariya Rozenblit

University of New Haven — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index1.5kcitations40works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(11), Nonmelanoma Skin Cancer Studies(10), Head and Neck Cancer Studies(8), Cancer Immunotherapy and Biomarkers(7), Dermatology and Skin Diseases(6)

Publications40 total

Abstract RF5-06: Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial
Clinical Cancer Research·2026
Abstract P4-03-29: Patient reported anxiety levels during ctDNA surveillance in early stage triple negative and hormone positive breast cancer
Clinical Cancer Research·2025· 1 cited
Abstract P2-03-27: Prevalence of actionable genomic alterations (GA) and predictive value of tumor mutational burden (TMB) for immune checkpoint inhibitor (ICI) effectiveness in HR(+)HER2(-) metastatic breast cancer (MBC)
Clinical Cancer Research·2025
Quantifying the clinical impact of tissue reflex testing for liquid biopsy <i>ESR1</i> mutation–negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer.
Journal of Clinical Oncology·2025
Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers
Cancer Medicine·2025· 7 citedOpen Access
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology
ESMO Open·2024· 4 citedOpen Access
Trends in breast cancer death by stage at diagnoses in 2000-2018.
Journal of Clinical Oncology·2023· 1 cited
The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas
Human Pathology·2023· 4 cited
Supplementary Data from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
2023Open Access
Data from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
2023Open Access
Data from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
2023Open Access
Supplementary Data from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
2023Open Access
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
npj Breast Cancer·2022· 25 citedOpen Access
Revisiting the bad luck hypothesis: Cancer risk and aging are linked to replication-driven changes to the epigenome
2022· 2 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Lajos Pusztai(19), Kim Blenman(15), Julia Foldi(14), Michał Marczyk(14), David L. Rimm(12), Andrea Silber(12), Thomas Karn(11), Vignesh Gunasekharan(11), Qing Tao(10), Xiaotong Li(10), Vesal Yaghoobi(10), Yalai Bai(10), Eiman Ibrahim(10), Tristen Park(10), Denise M. Wolf(10), Emily Reisenbichler(10), Carsten Denkert(10), Bruno V. Sinn(10), Sibylle Loibl(10), Emma Guttman‐Yassky(7)